Elucidating the Role of TREM2 in Alzheimer’s Disease

Slides:



Advertisements
Similar presentations
Treating the Developing versus Developed Brain: Translating Preclinical Mouse and Human Studies B.J. Casey, Charles E. Glatt, Francis S. Lee Neuron Volume.
Advertisements

The Pathobiology of Vascular Dementia Costantino Iadecola Neuron Volume 80, Issue 4, Pages (November 2013) DOI: /j.neuron Copyright.
Decision Making as a Window on Cognition Michael N. Shadlen, Roozbeh Kiani Neuron Volume 80, Issue 3, Pages (October 2013) DOI: /j.neuron
Eph-Ephrin Bidirectional Signaling in Physiology and Disease Elena B. Pasquale Cell Volume 133, Issue 1, Pages (April 2008) DOI: /j.cell
Neuronal Cell Types and Connectivity: Lessons from the Retina H. Sebastian Seung, Uygar Sümbül Neuron Volume 83, Issue 6, Pages (September 2014)
Molecular Motors in Neurons: Transport Mechanisms and Roles in Brain Function, Development, and Disease Nobutaka Hirokawa, Shinsuke Niwa, Yosuke Tanaka.
Reading the Book of Memory: Sparse Sampling versus Dense Mapping of Connectomes H. Sebastian Seung Neuron Volume 62, Issue 1, Pages (April 2009)
Syed H. Omar, Christopher J. Scott, Adam S. Hamlin, Hassan K. Obied 
The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease  Konrad Talbot, Hoau-Yan Wang 
The Neuropathology and Neurobiology of Traumatic Brain Injury
The Neuropathology and Neurobiology of Traumatic Brain Injury
Volume 48, Issue 6, Pages (December 2005)
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
Acetylation Unleashes Protein Demons of Dementia
Sphingolipid Signaling in Metabolic Disorders
Testing the Amyloid Hypothesis with a Humanized AD Mouse Model
Taking Advantage of the Systemic Immune System to Cure Brain Diseases
Probing the Biology of Alzheimer's Disease in Mice
A Flt3L Encounter: mTOR Signaling in Dendritic Cells
Mark S. Forman, Virginia M-Y. Lee, John Q. Trojanowski  Neuron 
An Element of Life: Competition for Zinc in Host-Pathogen Interaction
Mechanisms of Neuronal Degeneration in Alzheimer's Disease
Great Expectations for PIP: Phosphoinositides as Regulators of Signaling During Development and Disease  Lara C. Skwarek, Gabrielle L. Boulianne  Developmental.
α-Synuclein and Tau: Mitochondrial Kill Switches
Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder  Amy L. Mahan, Kerry J. Ressler  Trends in Neurosciences 
There's More Than One Way to Scale a Synapse
Applying the Brakes: When to Stop Eating
Emotional Pain without Sensory Pain—Dream On?
Treating Obesity? It's in the Bag!
Tara L. Spires-Jones, Bradley T. Hyman  Neuron 
Huntington's Disease: Can Mice Lead the Way to Treatment?
Todd E. Golde, Lon S. Schneider, Edward H. Koo  Neuron 
Jason D. Ulrich, Tien-Phat Huynh, David M. Holtzman  Neuron 
Volume 80, Issue 2, Pages (October 2013)
A Remarkable Facilitating Effect of Parietal Damage
Eukaryotic Transcription Activation: Right on Target
Advances in the War on Alzheimer's
Biomarker Modeling of Alzheimer’s Disease
The Role of Apolipoprotein E in Alzheimer's Disease
K+ Channel Regulation of Multicompartmental Signal Integration
Syk-coupled C-type lectins in immunity
A Developmental Switch in Microglial HDAC Function
A Sequel to the Tale of p25/Cdk5 in Neurodegeneration
Volume 91, Issue 1, Pages 1-3 (July 2016)
Chengcheng Jin, Jorge Henao-Mejia, Richard A. Flavell  Cell Metabolism 
Jee Hoon Roh, David M. Holtzman  Neuron 
Live Longer sans the AT1A Receptor
Volume 78, Issue 1, Pages 1-3 (April 2013)
Rab GTPases and Membrane Trafficking in Neurodegeneration
Proteins Kinases: Chromatin-Associated Enzymes?
Rik van der Kant, Lawrence S.B. Goldstein  Developmental Cell 
A Tale of Two Genes: Microglial Apoe and Trem2
Volume 52, Issue 1, Pages (October 2006)
The TORC that Gets the GC Cycling
Fyn-Tau-Amyloid: A Toxic Triad
Golgi Feels DNA’s Pain Cell
Death in the CNS: Six-Microns-Under
The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease  Konrad Talbot, Hoau-Yan Wang 
How does brain insulin resistance develop in Alzheimer's disease?
Biological Roles of Neutrophil-Derived Granule Proteins and Cytokines
Role reversal: Brain insulin and liver STAT3
Taking LSD1 to a New High Cell
Linking Calcium to Aβ and Alzheimer's Disease
Volume 84, Issue 5, Pages (December 2014)
BDNF (I)rising from Exercise
David Hubel and Torsten Wiesel
PKC Defends Crown Against Munc13
Nicolas Unsain, Philip A. Barker  Neuron 
Dendritic Tau in Alzheimer’s Disease
Melanocytes: A Window into the Nervous System
Presentation transcript:

Elucidating the Role of TREM2 in Alzheimer’s Disease Jason D. Ulrich, Tyler K. Ulland, Marco Colonna, David M. Holtzman  Neuron  Volume 94, Issue 2, Pages 237-248 (April 2017) DOI: 10.1016/j.neuron.2017.02.042 Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 1 Schematic of TREM2 and DAP12 Variants in the extracellular region of TREM2 are associated with NHD (red) and AD (green). Several AD-associated variants lie within a region that forms a basic-patch on the surface of TREM2 (blue box) that is thought to be critical for association with anionic ligands, such as anionic phospholipids. The transmembrane regions of TREM2 and DAP12 associate through a lysine-aspartate electrostatic interaction. DAP12 contains an ITAM region that, upon phosphorylation, recruits Syk to mediate downstream signal transduction. Neuron 2017 94, 237-248DOI: (10.1016/j.neuron.2017.02.042) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 2 Functional Effects of TREM2 Variants TREM2 variants associated with NHD or AD impact the expression, ligand binding affinity, and signaling efficacy of TREM2. TREM2 signaling via DAP12 can be activated by anionic phosopholipids, such as found in lipoprotein particles. Upon stimulation, Syk is recruited to DAP12 resulting in the downstream activation of PI3K, MAPKs, and elevations in intracellular Ca2+. The T66M TREM2 variant that is associated with NHD severely disrupts the proper folding of the TREM2 ectodomain. Heterologously expressed TREM2-T66M exhibits decreased surface expression, impaired trafficking, and intracellular aggregation. The AD-associated TREM2 variants, R47H and R62H, do not appear to alter the surface expression of TREM2. However, both variants decrease the affinity of TREM2 for lipid ligands and lipid-induced TREM2 activation. In contrast, the T96K variant exhibits increased affinity for lipids and an increased responsiveness to lipid stimulation. Interestingly, cells expressing TREM2-R47H and TREM2-R62H also exhibited reduced uptake of lipoprotein particles. Whether TREM2 directly mediates lipoprotein uptake has not yet been determined. Neuron 2017 94, 237-248DOI: (10.1016/j.neuron.2017.02.042) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 3 Schematic of Changes in CSF Levels of sTREM2, Aβ42, and p-tau in AD Amyloid plaques begin to deposit in the brain 15–25 years prior to the onset of cognitive symptoms. CSF levels of Aβ42 decline during this preclinical period, likely due to sequestration of Aβ42 into amyloid plaques. Subsequently, CSF levels of tau and p-tau increase, which likely reflects increased neuronal damage, and these increases coincide with the onset of MCI and dementia associated with AD. CSF levels of sTREM2 appear to correlate with the CSF levels of tau and p-tau as well as the onset of cognitive decline, but not with CSF levels of Aβ42. CSF sTREM2 levels may reflect significant levels of microgliosis and inflammation related to neurodegeneration due to AD pathology. Neuron 2017 94, 237-248DOI: (10.1016/j.neuron.2017.02.042) Copyright © 2017 Elsevier Inc. Terms and Conditions